Periodic Reporting for period 1 - GLIOGUIDE (Commercialising a novel glioblastoma targeted therapy and a companion diagnostic compound)
Reporting period: 2018-06-01 to 2019-11-30
In GLIOGUIDE-supported Proof-of-concept studies, we developed two types of tumor-targeted PL1-payload hybrids, one as an improved anticancer treatment, and the other as a precision-guided contrast agent for imaging-based diagnosis and patient stratification. The goal was for the former to become the clinician’s chemotherapy of choice in the adjuvant phase of GBM treatment; and for the latter to be incorporated into MR-imaging procedures as a method for identifying and diagnosing GBM, as well as a companion test for stratification of patients for PL1-based therapy. These proof-of-concept studies were accompanied by activities on (1) IP and regulatory preparation and submission, and (2) commercial feasibility assessment.
The proposed work has validated the GBM-targeting characteristics and translational potential of PL-guided imaging and therapeutic compounds for improved glioma detection and treatment. At the current stage we are working on additional Investigational New Drug (IND)-enabling studies to develop PL1-guided compounds towards clinical applications.